$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

$iova Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000114420418057663 Filed on November 06, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.530M	$7.110M	$4.590M
YoY Change	-11.31%	54.9%	-56.29%
% of Gross Profit
Research & Development	$27.42M	$27.95M	$16.68M
YoY Change	55.88%	67.56%	96.66%
% of Gross Profit
Depreciation & Amortization	$260.0K	$250.0K	$250.0K
YoY Change	8.33%	0.0%	66.67%
% of Gross Profit
Operating Expenses	$34.94M	$35.06M	$22.34M
YoY Change	34.02%	56.92%	17.72%
Operating Profit		-$35.06M	-$22.34M
YoY Change		56.92%	17.72%
Interest Expense	$2.370M	$1.230M	$190.0K
YoY Change	977.27%	547.37%	-13.64%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$32.58M	-$33.83M	-$22.15M
YoY Change	26.03%	52.73%	18.07%
Income Tax
% Of Pretax Income
Net Earnings	-$32.58M	-$33.83M	-$22.15M
YoY Change	26.0%	52.74%	-67.53%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$273.0K	-$355.8K	-$349.8K
COMMON SHARES
Basic Shares Outstanding	123.2M shares	95.59M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$468.5M	$260.0M	$163.4M
YoY Change	222.21%	59.12%	-8.87%
Cash & Equivalents	$82.15M	$80.74M	$163.4M
Short-Term Investments	$386.4M	$179.3M	$0.00
Other Short-Term Assets	$6.900M	$5.900M	$8.000M
YoY Change	76.92%	-26.25%	515.38%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$475.4M	$265.9M	$171.4M
YoY Change	218.42%	55.11%	-5.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.683M	$2.640M	$2.600M
YoY Change	9.51%	1.54%	46.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.764M	$2.331M
YoY Change	-23.92%
Total Long-Term Assets	$5.447M	$4.971M	$2.600M
YoY Change	-10.46%	91.19%	46.98%
TOTAL ASSETS
Total Short-Term Assets	$475.4M	$265.9M	$171.4M
Total Long-Term Assets	$5.447M	$4.971M	$2.600M
Total Assets	$480.8M	$270.8M	$174.0M
YoY Change	209.46%	55.65%	-4.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.739M	$6.014M	$2.900M
YoY Change	122.32%	107.38%	1171.93%
Accrued Expenses	$11.66M	$10.66M	$5.600M
YoY Change	39.41%	90.36%	88.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.40M	$16.67M	$8.500M
YoY Change	50.06%	96.16%	166.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$230.0K
YoY Change	-23.33%
Total Long-Term Liabilities	$230.0K	$0.00	$0.00
YoY Change	-22.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.40M	$16.67M	$8.500M
Total Long-Term Liabilities	$230.0K	$0.00	$0.00
Total Liabilities	$14.63M	$16.70M	$8.500M
YoY Change	47.88%	96.47%	165.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$372.8M	-$340.2M
YoY Change	49.59%
Common Stock	$5.000K	$4.000K
YoY Change	66.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$466.2M	$254.2M	$165.4M
YoY Change
Total Liabilities & Shareholders Equity	$480.8M	$270.8M	$174.0M
YoY Change	209.46%	55.65%	-4.55%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$32.58M	-$33.83M	-$22.15M
YoY Change	26.0%	52.74%	-67.53%
Depreciation, Depletion And Amortization	$260.0K	$250.0K	$250.0K
YoY Change	8.33%	0.0%	66.67%
Cash From Operating Activities	-$31.55M	-$27.93M	-$21.45M
YoY Change	50.52%	30.21%	75.68%
INVESTING ACTIVITIES
Capital Expenditures	-$300.0K	-$460.0K	-$270.0K
YoY Change	-600.0%	70.37%	-62.5%
Acquisitions
YoY Change
Other Investing Activities	-$206.1M	-$148.9M	$14.75M
YoY Change		-1109.56%	-194.37%
Cash From Investing Activities	-$206.4M	-$149.4M	$14.49M
YoY Change	-344066.67%	-1130.92%	-188.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$236.7M		$53.70M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	239.4M	12.02M	56.06M
YoY Change	8153.45%	-78.56%	11112.0%
NET CHANGE
Cash From Operating Activities	-31.55M	-27.93M	-21.45M
Cash From Investing Activities	-206.4M	-149.4M	14.49M
Cash From Financing Activities	239.4M	12.02M	56.06M
Net Change In Cash	1.420M	-165.3M	49.10M
YoY Change	-107.89%	-436.64%	-274.98%
FREE CASH FLOW
Cash From Operating Activities	-$31.55M	-$27.93M	-$21.45M
Capital Expenditures	-$300.0K	-$460.0K	-$270.0K
Free Cash Flow	-$31.25M	-$27.47M	-$21.18M
YoY Change	48.67%	29.7%	84.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80738000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	145373000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5863000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3917000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	265863000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	149290000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2640000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2450000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2331000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3633000	USD
CY2018Q3	us-gaap	Assets Assets	270834000	USD
CY2017Q4	us-gaap	Assets Assets	155373000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6014000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1232000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	16674000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9892000	USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20905000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15887000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	35060000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	22343000	USD
	us-gaap	Operating Expenses OperatingExpenses	93315000	USD
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	5516000	USD
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	2619000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	14842000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	9208000	USD
CY2018Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	26334000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	594455000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	394651000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-340185000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-249180000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	254160000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	145481000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	270834000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155373000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13372777	shares
CY2018Q3	us-gaap	Revenues Revenues	0	USD
CY2017Q3	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27947000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16679000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72410000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50919000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7113000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5664000	USD
CY2017Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	91281000	USD
CY2018Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2897000	USD
CY2017Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2613000	USD
CY2018Q3	iova	Legal And Related Services Current LegalAndRelatedServicesCurrent	498000	USD
CY2017Q4	iova	Legal And Related Services Current LegalAndRelatedServicesCurrent	935000	USD
CY2018Q3	iova	Clinical Related Expenses Current ClinicalRelatedExpensesCurrent	4029000	USD
CY2017Q4	iova	Clinical Related Expenses Current ClinicalRelatedExpensesCurrent	3310000	USD
CY2018Q3	iova	Manufacturing Related Expenses Current ManufacturingRelatedExpensesCurrent	2442000	USD
CY2017Q4	iova	Manufacturing Related Expenses Current ManufacturingRelatedExpensesCurrent	876000	USD
CY2018Q3	us-gaap	Accrued Rent Current AccruedRentCurrent	335000	USD
CY2017Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	430000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	459000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	496000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10660000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8660000	USD
	us-gaap	Operating Expenses OperatingExpenses	66806000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-35060000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-22343000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-93315000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-66806000	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1230000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	194000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2310000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	596000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-91005000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.01
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.06
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	95077	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	63332	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89927	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62697	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	137500	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	80200	shares
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	38500000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y11M8D
CY2018Q3	us-gaap	Share Based Compensation ShareBasedCompensation	5400000	USD
CY2017Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2600000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.26
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.46
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3800000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1200000	USD
CY2018Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	179262000	USD
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	0	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-120000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-33830000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-22149000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-117000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-120000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33947000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22149000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-91125000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	704000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	710000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-9000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-388000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	19000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14842000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9208000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	644000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4953000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4782000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2148000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2000000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1333000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69700000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-57745000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	903000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	59705000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1086000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-179897000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	58619000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	181000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1203000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	14684000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	388000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8366000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2554000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	162093000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	54050000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	184962000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55789000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-64635000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	56663000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106717000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	163380000	USD
	iova	Unrealized Gain Loss On Shortterm Investments UnrealizedGainLossOnShorttermInvestments	-120000	USD
	iova	Unrealized Gain Loss On Shortterm Investments UnrealizedGainLossOnShorttermInvestments	-29000	USD
	iova	Leasehold Improvements Paid By Landlord LeaseholdImprovementsPaidByLandlord	0	USD
	iova	Leasehold Improvements Paid By Landlord LeaseholdImprovementsPaidByLandlord	-155000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	178994000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	iova	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	23100000	USD
CY2018Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	179262000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	179262000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	0	USD
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	1523396	shares
	iova	Reversal Of Prior Period Expense ReversalOfPriorPeriodExpense	400000	USD
CY2016Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	500000	USD
	iova	Common Stock Registered For Resale CommonStockRegisteredForResale	128500	shares
	iova	Number Of Share Options Or Share Units Exercised During Current Period NumberOfShareOptionsOrShareUnitsExercisedDuringCurrentPeriod	128500	shares
CY2018Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2017Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	USD
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000041666
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97425721	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73164914	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000041666
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97425721	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73164914	shares
	us-gaap	Net Income Loss NetIncomeLoss	-66210000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-29000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66239000	USD
	iova	Offering Costs Under Accounts Payable And Accrued Expenses OfferingCostsUnderAccountsPayableAndAccruedExpenses	0	USD
	iova	Offering Costs Under Accounts Payable And Accrued Expenses OfferingCostsUnderAccountsPayableAndAccruedExpenses	235000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	The granted stock options vest in 12 quarterly installments (with 1/12th of the option shares having vested on the date of grant).
CY2018Q3	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	178994000	USD
	iova	Trading Securities Accretion TradingSecuritiesAccretion	388000	USD
CY2018Q3	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	0	USD
CY2018Q3	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	120000	USD
CY2018Q3	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	179262000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	IOVA
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	123169528	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 8. LEGAL PROCEEDINGS</div></div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Class Action Lawsuit.</div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> On April 10, 2017, the SEC announced settlements with </div>the Company <div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">and with other public companies and unrelated parties in the <div style="font-style:italic;display:inline;">In the Matter of Certain Stock Promotion </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">investigation. </div>The Company’s <div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">settlement with the SEC is consistent with our previous disclosures (including in our Annual Report on Form 10-K that we filed with the SEC on March 9, 2017). On April 14, 2017, a purported shareholder filed a complaint seeking class action status in the United States District Court, Northern District of California for violations of the federal securities laws (</div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leonard DeSilvio v. Lion Biotechnologies, Inc., et al., </div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">case no. 3:17-cv-2086) against our company and three of our former officers and directors. On April 19, 2017, a second class action complaint </div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(Amra Kuc vs. Lion Biotechnologies, Inc., et al., </div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">case no. 3:17-cv-2188) was filed in the same court. Both complaints allege, among other things, that the defendants violated the federal securities laws by making materially false and misleading statements, or by failing to make certain disclosures, regarding the actions taken by Manish Singh, our former CEO, and our former investor relations firm that were the subject of the </div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In the Matter of Certain Stock Promotions </div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">investigation. On July 20, 2017, the plaintiff in the </div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Kuc </div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">case filed a notice to voluntarily dismiss that case. The court entered an order dismissing the </div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Kuc </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">complaint on July 21, 2017. On July 26, 2017, the court appointed a movant as lead plaintiff. On September 8, 2017, the lead plaintiff filed an amended complaint (</div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jay Rabkin v. Lion Biotechnologies, Inc., et al., </div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">case no. 3:17-cv-2086) seeking class action status that alleges, among other things, that the defendants violated federal securities laws by making materially false and misleading statements, or by failing to make certain disclosures, regarding the actions taken by Manish Singh and our former investor relations firm that were the subject of the </div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In the Matter of Certain Stock Promotions </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">SEC investigation. On February 5, 2018, the court entered an order dismissing two of plaintiff’s six claims. As the result of mediation, on September 28, 2018, lead plaintiff filed an unopposed motion for settlement, the cost of which, if approved, is expected to be borne by our insurance carrier and would result in no loss to us. A hearing on preliminary approval of the settlement is set for November 9, 2018.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Derivative Lawsuits.</div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> On December 15, 2017, a purported stockholder derivative complaint was filed by plaintiff Kevin Fong on behalf of the Company, against the Company, as nominal defendant, and certain of the Company’s current and former officers and directors, and others, as defendants, in the U.S. District Court for the District of Delaware (case no. 1:17-cv-1806). The complaint alleges breaches of fiduciary duties, unjust enrichment, and violations of Section 14(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder arising from the SEC’s investigation in the </div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In the Matter of Certain Stock Promotions </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">investigation and our April 10, 2017 settlement thereof, and seeks unspecified damages on behalf of our company and injunctive relief.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On March 28, 2018, a purported stockholder derivative complaint was filed by plaintiff Nazeer Khaleeluddin on behalf of the Company, against the Company, as nominal defendant, and certain of the Company’s current and former officers and directors, and others, as defendants, in the U.S. District Court for the District of Delaware (case no. 1:18-cv-00469). The complaint alleges, among other things, violations of securities law, breach of fiduciary duty, aiding and abetting, waste of corporate assets, and unjust enrichment. The complaint is based on claims arising from the SEC’s investigation in the </div><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In the Matter of Certain Stock Promotions</div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> investigation and the Company’s April 10, 2017 settlement thereof, and seeks unspecified damages on behalf of our company and injunctive relief. On May 1, 2018, the court consolidated this case with the aforementioned purported stockholder derivative case filed by plaintiff Kevin Fong.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt "times new roman", times, serif; background: none;">The Company intends <div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">to vigorously defend against the foregoing complaints. Based on the very early stage of the litigation, it is not possible to estimate the amount or range of possible loss that might result from an adverse judgment or a settlement of these matters.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Solomon Capital, LLC.</div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> On April 8, 2016, a lawsuit titled </div><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Solomon Capital, LLC, Solomon Capital 401(K) Trust, Solomon Sharbat and Shelhav Raff v. Lion Biotechnologies, Inc.</div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> was filed by Solomon Capital, LLC, Solomon Capital 401(k) Trust, Solomon Sharbat and Shelhav Raff against the Company in the Supreme Court of the State of New York, County of New York (index no. 651881/2016). The plaintiffs allege that, between June and November 2012 they provided to the Company $0.1 million and that they advanced and paid on our behalf an additional $0.2 million. The complaint further alleges that the Company agreed to (i) provide them with promissory notes totaling $0.2 million, plus interest, (ii) issue a total of 111,425 shares to the plaintiffs (before the 1-for-100 reverse split of our common stock effected in March 2013), and (iii) allow the plaintiffs to convert the foregoing funds into our securities in the next transaction. The plaintiffs allege that they should have been able to convert their advances and payments into shares of the Company’s common stock in the restructuring that was affected in May 2013. Based on the foregoing, the plaintiffs allege causes for breach of contract and unjust enrichment and demand judgment against the Company in an unspecified amount exceeding $1.5 million, plus interest and attorneys’ fees.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On June 3, 2016, the Company filed an answer and counterclaims in the lawsuit. In its counterclaims, the Company alleges that the plaintiffs misrepresented their qualifications to assist it in fundraising and that they failed to disclose that they were under investigation for securities laws violations. The Company is seeking damages in an amount exceeding $0.5 million and an order rescinding any and all agreements that the plaintiffs contend entitled them to obtain stock in the Company.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On April 19, 2017, the court granted plaintiffs’ counsel’s motion to withdraw from the case. On May 25, 2017, plaintiffs filed a notice that they had hired new counsel. On June 7, 2017, the judge presiding over the case recused herself because of a conflict of interest arising from her relationship with plaintiffs’ new attorneys, and the case was subsequently assigned to a new judge. On April 20, 2018, the court held a hearing regarding plaintiff’s motion to dismiss the Company’s amended counterclaims and affirmative defense for fraudulent inducement. On August 15, 2018, the court entered an order granting the plaintiff’s motion and dismissed the Company’s amended counterclaims and eleventh affirmative defense for fraudulent inducement without leave to amend. On September 14, 2018, the Company filed a notice of appeal related to this order, and on </div><div style="background: none; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">November 5, 2018, </div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">the Company filed its memorandum of law in support of its appeal of the order dismissing the Company’s amended counterclaims and affirmative defense for fraudulent inducement.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to vigorously defend the complaint and pursue its counterclaims.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Litigation Involving Dr. Steven Fischkoff.</div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> On June 13, 2017, in an action titled </div><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Steven Fischkoff v. Lion Biotechnologies, Inc. and Maria Fardis</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">, Dr. Steven Fischkoff, our former Vice President and Chief Medical Officer, filed a lawsuit against the Company and Dr. Fardis in the Supreme Court of the State of New York County of New York. Dr. Fischkoff was dismissed by the Company on March 28, 2017. Dr. Fischkoff was terminated “for cause” as that term is defined in his employment agreement. In his complaint, Dr. Fischkoff alleges breaches of his employment agreement and violation of New York Labor Law for failure to pay monies purportedly owed to him, and seeks to recover amounts including severance pay and retention bonus (totaling $300,000), a prorated incentive bonus, and amounts relating to unvested options to 150,000 shares of our common stock, together with prejudgment interest, costs, expenses and attorneys’ fees. On July 5, 2017, the Company filed a removal petition and removed the lawsuit to the United States District Court for the Southern District of New York, where the case has been assigned case no. 1:17-cv-05041. On July 14, 2017, the Company filed a partial answer and counterclaims against Dr. Fischkoff, denying his allegations, and alleging breach of contract and related claims, breach of fiduciary duty, and state and federal trade secret misappropriation and related claims, and sought a temporary restraining order and preliminary injunction against Dr. Fischkoff. On July 18, 2017, the court issued a temporary restraining order against Dr. Fischkoff requiring him to return Company materials, prohibiting him from disclosing or using Company materials, and granting expedited discovery. On June 25, 2018, pursuant to a stipulation between the parties, the court entered a permanent injunction prohibiting Dr. Fischkoff from disclosing, possessing, or using any of the Company’s proprietary materials or trade secrets. On July 5, 2018, the court entered an order dismissing two of Dr. Fischkoff’s claims against us and Dr. Fardis. On October 18, 2018, Dr. Fischkoff amended his complaint to assert a new claim for defamation arising from SEC filings in which the Company provided information about this litigation.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;">The Company intends<div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> to vigorously defend against Dr. Fischkoff’s lawsuit and pursue the Company’s counterclaims. Based on the very early stage of the litigation, it is not possible to estimate the amount or range of (i) a possible loss that might result from an adverse judgment or settlement of this action, or (ii) the potential recovery that might result from a favorable judgment or a settlement of this action.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Other Matters.</div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> During the second quarter of 2016, warrants representing 128,500 shares were exercised. The 128,500 shares of common stock had previously been registered for re-sale. However, we believe that these 128,500 warrant shares were sold by the holders in open market transactions in May 2016 at a time when the registration statement was ineffective. Accordingly, those sales were not made in accordance with Sections 5 and 10(a)(3) of the Securities Act</div> of 1933, as amended<div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">, and the purchasers of those shares may have rescission rights (if they still own the shares) or claims for damages (if they no longer own the shares). The amount of any such liability is uncertain and as such, an accrual for any potential loss has not been made. The Company believes that any claims brought against it would not result in a material impact to the Company’s financial position or results of operations. The Company has not accrued a loss for a potential claim associated with this matter as it is unable to estimate any at this time.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Company’s reincorporation from Nevada to Delaware in 2017, the Company (as a Delaware corporation) untimely filed a post-effective amendment to adopt a Form S-8 registration statement that the Company filed (as a Nevada corporation) to register the shares underlying the Company’s 2011 Equity Incentive Plan. Before the Company filed the required post-effective amendment, options to purchase 200,000 shares were exercised under the 2011 Equity Incentive Plan. The effect of the delayed post-effective amendment filing on the 200,000 option shares is uncertain, but the issuance and sale of the shares may not have been in compliance with the Form S-8 registration statement. The existence of any liability to the Company, and the amount of any such liability to the Company, as a result of the issuance of the 200,000 shares is uncertain. Accordingly, no accrual for a potential claim has been made by the Company in its financial statements.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company, management does not believe any pending matter will be resolved in a manner that would have a material adverse effect on the Company’s financial position, results of operations or cash flows.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	dei	Entity Small Business EntitySmallBusiness	false
CY2018Q3	iova	Payments For Legal Services PaymentsForLegalServices	100000	USD
	iova	Payments For Legal Services PaymentsForLegalServices	400000	USD
	iova	Payments For Legal Services PaymentsForLegalServices	500000	USD
CY2017Q3	iova	Payments For Legal Services PaymentsForLegalServices	100000	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	an amendment to increase the number options or other awards that can be granted to any one person during a twelve (12) month period from 50,000 shares to 300,000 shares.
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22038728	shares
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	IOVANCE BIOTHERAPEUTICS, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001425205
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin: 0px 0px 0px 0in; font-family: "times new roman", times, serif; font-size: 10pt; background: none;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: "times new roman", times, serif; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates</div></div></div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "times new roman", times, serif; font-size: 10pt; background: none;"><div style="font-size: 10pt; text-decoration: none; font-family: "times new roman", times, serif; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; text-indent: 0.5in; font-family: "times new roman", times, serif; font-size: 10pt; background: none;"><div style="font-size: 10pt; font-family: "times new roman", times, serif; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation of short-term investments, the useful lives of property and equipment, accounting for potential liabilities, the valuation allowance associated with the Company’s deferred tax assets, and the assumptions made in valuing stock instruments issued for services.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin: 0px 0px 0px 0in; font-family: "times new roman", times, serif; font-size: 10pt; background: none;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: "times new roman", times, serif; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Reclassifications</div></div></div></div><div style="margin: 0px 0px 0px 0in; font-family: "times new roman", times, serif; font-size: 10pt; background: none;"><div style="font-size: 10pt; text-decoration: none; font-family: "times new roman", times, serif; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; text-indent: 0.5in; font-family: "times new roman", times, serif; font-size: 10pt; background: none;"><div style="font-size: 10pt; font-family: "times new roman", times, serif; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain amounts within the statements of operations for the prior periods have been reclassified to conform with the current period presentation. These reclassifications had no impact on the Company's previously reported financial position or cash flows for any of the periods presented.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name	View Source	Status
0001144204-18-057663-index-headers.html	Edgar Link	pending
0001144204-18-057663-index.html	Edgar Link	pending
0001144204-18-057663.txt	Edgar Link	pending
0001144204-18-057663-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
iova-20180930.xml	Edgar Link	completed
iova-20180930.xsd	Edgar Link	pending
iova-20180930_cal.xml	Edgar Link	unprocessable
iova-20180930_def.xml	Edgar Link	unprocessable
iova-20180930_lab.xml	Edgar Link	unprocessable
iova-20180930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv505322_10q.htm	Edgar Link	pending
tv505322_ex31-1.htm	Edgar Link	pending
tv505322_ex31-2.htm	Edgar Link	pending
tv505322_ex32-1.htm	Edgar Link	pending
tv505322_ex32-2.htm	Edgar Link	pending
tv505322_img-01.jpg	Edgar Link	pending
tv505322_img-02.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

2018 Q4 Form 10-Q Financial Statement

#000114420418057663 Filed on November 06, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IOVA IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

2018 Q4 Form 10-Q Financial Statement

#000114420418057663 Filed on November 06, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova